Navigation Links
OncoSec Closes $7.75 Million Public Offering
Date:3/28/2012

SAN DIEGO, March 28, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today the closing of the sale to institutional investors of an aggregate of 31,000,000 shares of its common stock at $0.25 per share in a registered public offering.  Additionally, investors received Warrants to purchase up to 31,000,000 shares of common stock at an exercise price of $0.35 per share for a term of five years.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The gross proceeds of the offering were $7.75 million and net proceeds, after deducting the placement agent's fee and estimated offering expenses payable by OncoSec, were approximately $7.2 million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), acted as the exclusive placement agent for the transaction.  Roth Capital Partners, LLC served as financial advisors to the Company in the offering.

About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and ot
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoSec to Present at 10th Annual BioPartnering North America
2. OncoSec Medical Reports Third Quarter 2011 Financial Results
3. OncoSec Announces Clinical Leadership Appointments
4. OncoSec Announces Leadership Team Appointments
5. OncoSec Medical Featured in Medical Device Daily
6. OncoSec Medical Appoints Punit Dhillon as President and CEO
7. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
8. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
9. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
10. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
11. Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Esperance Pharmaceuticals Inc. today reported positive results ... in ovarian cancer patients resistant to paclitaxel. EP-100 is ... cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) receptors ... wide range of cancers. Results of ... were presented at the 2015 ASCO Annual Meeting ...
(Date:6/1/2015)... 29, 2015 Research and Markets ... of the "2015 Strategies in European ... their offering. This new 273-page ... diagnostic market, including emerging tests, technologies, instrumentation, ... of leading suppliers. Companies Mentioned: ...
(Date:6/1/2015)... Research and Markets( http://www.researchandmarkets.com/research/5j2hpk/2015_strategies ) ... "2015 Strategies in the US Point-of-Care/POC Clinical ... This new 373-page report contains ... of the POC clinical chemistry market, including ... trends, competitive landscape, and emerging opportunities for ...
(Date:6/1/2015)... Research and Markets( http://www.researchandmarkets.com/research/n2rvxp/2015_assessments ) ... "2015 Assessments of Leading Microbiology Market Players--Insightful ... Entrants" report to their offering. ... provides insightful profiles of leading microbiology market ... The report presents strategic assessments, including sales, ...
Breaking Biology Technology:Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3Assessments of Leading Microbiology Market Players 2015 - Profiles of Major Suppliers and Recent Market Entrants 2
... - CEO Michael V. Novinski to Discuss Plans ... CEDAR KNOLLS, N.J., Jan. 31 Emisphere,Technologies, Inc. ... will host a,teleconference on Thursday, February 7, at ... V. Novinski will discuss the company,s,emerging business strategy. ...
... Names Board of Directors, SAN DIEGO, Jan. ... developing therapeutics for the,treatment of Alzheimer,s disease, announced ... Series A round of financing. The financing was ... Alta Partners. Additional,investors included AgeChem Venture Fund, and ...
... Foundation Continues Research Initiatives in Search of a Cure and Therapies ... ... N.J., Jan. 31 The Christopher and Dana,Reeve Foundation (CDRF), which ... improving the quality of life for people,living with paralysis through grants, ...
Cached Biology Technology:Emisphere to Host Business Strategy Conference Call on February 7 2Emisphere to Host Business Strategy Conference Call on February 7 3Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 2Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 3Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 2Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 3
(Date:5/14/2015)... May 14, 2015 Research and Markets ... "Fingerprint Sensors Market in Smart Mobile Devices " ... believes that 2014 was a watershed year for fingerprint ... of ,Apple Pay,. Apple gave fingerprint sensors a raison ... service. Fingerprint sensors are a must-have feature in flagship ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... of an unknown perpetrator who has committed a crime will ... MC scientists, in collaboration with their Polish colleagues, have discovered ... color. Their findings will be published today in the Springer ... that on the basis of DNA information it is possible ...
... (PHILADELPHIA) An international team of researchers led ... Penn Medicine,s Institute for Translational Medicine and Therapeutics, ... Paris-based Fondation Leducq to study the molecular genetics ... Mechanisms of Novel Genes Associated with Plasma Lipids ...
... Many young people who,ve just learned that they have cancer ... lives could rob them of their ability ever to have ... population: Of the 1.5 million people diagnosed with cancer in ... The good news, according to an article in ...
Cached Biology News:Hair color of unknown offenders is no longer a secret 2Penn Medicine researcher receives $6 million grant for cardiovascular disease study 2Advancements in fertility preservation provide oncology patients new options 2Advancements in fertility preservation provide oncology patients new options 3
... Science LAS-3000 imaging system combines new ... user interface, providing significantly improved system ... modularities. The system is especially dedicated ... standard system for Western blotting applications.,Fuiji's ...
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
... m7G Capping system features the ... of the components needed to ... the end of di- or ... feature high efficiency capping (virtually ...
... Removal , , Removes ... cross-reactivity with other proteins , Simple, just ... Economical new surface technology, not based on ... with protein analysis. SurfactAway offers a simple ...
Biology Products: